GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » EBIT

Cytokinetics (Cytokinetics) EBIT : $-468.85 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics EBIT?

Cytokinetics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-118.32 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-468.85 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cytokinetics's annualized ROC % for the quarter that ended in Mar. 2024 was -208.07%. Cytokinetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -322.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cytokinetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -7.39%.


Cytokinetics EBIT Historical Data

The historical data trend for Cytokinetics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics EBIT Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.33 -88.61 -185.98 -337.80 -468.58

Cytokinetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -118.05 -115.27 -115.43 -119.83 -118.32

Competitive Comparison of Cytokinetics's EBIT

For the Biotechnology subindustry, Cytokinetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cytokinetics's EV-to-EBIT falls into.



Cytokinetics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-468.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytokinetics  (NAS:CYTK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cytokinetics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-504.94 * ( 1 - 0% )/( (264.05 + 221.31)/ 2 )
=-504.94/242.68
=-208.07 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=824.316 - 34.893 - ( 614.824 - max(0, 102.678 - 628.051+614.824))
=264.05

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=808.082 - 36.923 - ( 618.961 - max(0, 88.855 - 638.704+618.961))
=221.31

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cytokinetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-473.288/( ( (147.735 + max(-61.48, 0)) + (146.188 + max(-39.362, 0)) )/ 2 )
=-473.288/( ( 147.735 + 146.188 )/ 2 )
=-473.288/146.9615
=-322.05 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.283 + 0 + 11.944) - (34.893 + 0 + 39.814)
=-61.48

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.834 + 0 + 18.909) - (36.923 + 0 + 22.182)
=-39.362

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cytokinetics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-468.85/6346.453
=-7.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytokinetics EBIT Related Terms

Thank you for viewing the detailed overview of Cytokinetics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (Cytokinetics) Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Executives
Robert I Blum officer: EVP, Corp. Development & CBO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik officer: SVP Research & Early Dev 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong officer: VP, Chief Accounting Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw officer: SVP Finance & CFO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa director
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington director C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg officer: SVP - Legal & General Counsel C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg officer: V.P., Human Resources 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044